Kathy Oubre, MS, considers how comfortable physicians and payers are with biosimilars

Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, considers how comfortable physicians and payers are with biosimilars

Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, considers how comfortable physicians and payers are with biosimilars

Kathy Oubre, MS, speculates on the future of biosimilars

Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, speculates on the future of biosimilars

Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, speculates on the future of biosimilars

Kathy Oubre, MS, offers opinion on whether biosimilars are living up to their estimated cost savings

Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, offers opinion on whether biosimilars are living up to their estimated cost savings

Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, offers opinion on whether biosimilars are living up to their estimated ...

Kathy Oubre, MS, comments on the recent criticism regarding the use of biosimilars

Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, comments on recent criticisms surrounding biosimilars

Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, comments on recent criticisms surrounding biosimilars

Bo Gamble, on the most important critical success factors when adopting a new payment model

Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, offers opinion on the most important critical success factors when adopting a new payment model

Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, offers opinion on the most important critical success factors when ...

Alti Rahman, MHA\MBA, CSSBB, reflects on social determinants of health in cancer care

Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, reflects on social determinants of health and considers how an oncology practice can remain efficient and sensitive to patients who have just received a cancer diagnosis

Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, reflects on social determinants of health and considers how an oncology practice ...

Bo Gamble, discusses the impact of consolidation on the delivery of cancer care

Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, discusses the impact of consolidation on the delivery of cancer care and on alterative payment models (APMs)

Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, discusses the impact of consolidation on the delivery of cancer ...

Bo Gamble, speculates on the future of alternative payment models (APMs)

Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, speculates on the future of alternative payment models (APMs) and explains how a practice can determine which APMs are most appropriate to pursue

Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, speculates on the future of alternative payment models (APMs) and ...

Alti Rahman, MHA\MBA, CSSBB, offers advice to oncology practices in today's cancer care landscape

Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, offers advice to oncology practices looking to succeed in today's landscape of cancer care

Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, offers advice to oncology practices looking to succeed in today's landscape of ...

Alti Rahman, MHA\MBA, CSSBB, regarding the impact of consolidation on the delivery of cancer care

Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, regarding the impact of consolidation on the delivery of cancer care

Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, regarding the impact of consolidation on the delivery of cancer care